ArticlebioRxiv : the preprint server for biology2026
Keratin 5 marks cancer-propagating cells sustained by an osteopontin-producing niche in high-grade serous ovarian carcinoma.
Mallikarjun Bidarimath, Coulter Q Ralston, Nandini Bidarimath, Ian M Rose, Darianna Colina, Elisa Schmoeckel, Andrew K Godwin, Doris Mayr, Lora H Ellenson, Andrea Flesken-Nikitin and 1 more
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
11 authors.
Mallikarjun BidarimathDepartment of Biomedical and Translational Sciences, Cornell University, Ithaca, New York, USA.ORCID 0000-0002-9080-8737 Coulter Q RalstonDepartment of Biomedical and Translational Sciences, Cornell University, Ithaca, New York, USA.ORCID 0000-0003-2093-6482 Nandini BidarimathDepartment of Biomedical and Translational Sciences, Cornell University, Ithaca, New York, USA.
Ian M RoseDepartment of Biomedical and Translational Sciences, Cornell University, Ithaca, New York, USA.
Darianna ColinaDepartment of Biomedical and Translational Sciences, Cornell University, Ithaca, New York, USA.
Elisa SchmoeckelInstitute of Pathology, Ludwig Maximilians University, Munich, Germany.
Andrew K GodwinPathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Doris MayrInstitute of Pathology, Ludwig Maximilians University, Munich, Germany.
Lora H EllensonMemorial Sloan Kettering Cancer Center, New York, USA.
Andrea Flesken-NikitinDepartment of Biomedical and Translational Sciences, Cornell University, Ithaca, New York, USA.ORCID 0000-0003-3017-1399 Alexander Yu NikitinDepartment of Biomedical and Translational Sciences, Cornell University, Ithaca, New York, USA.ORCID 0000-0002-3729-7982 Funding
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1MUsing Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Diane E Mahoney · 2019 to 2026
$21.5MEndometrial epithelial stem cells and cancerR01CA248524 · NCI · CORNELL UNIVERSITY · PI NIKITIN, ALEXANDER Y. · 2021 to 2025
$2.1MCancer-prone cell states of the fallopian tubal epitheliumR01CA260115 · NCI · CORNELL UNIVERSITY · PI NIKITIN, ALEXANDER Y. · 2021 to 2025
$2.1MOrigins of Ovarian CarcinomaR01CA182413 · NCI · CORNELL UNIVERSITY · PI NIKITIN, ALEXANDER Y. · 2015 to 2019
$1.8MModeling ovarian carcinoma by defined genetic alterationsR01CA112354 · NCI · CORNELL UNIVERSITY ITHACA · PI NIKITIN, ALEXANDER Y. · 2005 to 2009
$1.4MResearch and Career Training in Vertebrate Developmental GenomicsT32HD057854 · NICHD · CORNELL UNIVERSITY · PI SCHIMENTI, JOHN C · 2010 to 2020
$1.3MNCI NIH HHS P30 CA168524NCI NIH HHS R01 CA112354NCI NIH HHS R01 CA182413NCI NIH HHS R01 CA248524NCI NIH HHS R01 CA260115NICHD NIH HHS T32 HD057854NIGMS NIH HHS P20 GM130423
6 · The paper itselfAbstract
High-grade serous carcinoma (HGSC) is the most common and aggressive form of ovarian cancer. Advanced HGSCs exhibit pronounced cellular heterogeneity, including a subset of cancer-propagating cells (CPCs, also known as cancer stem cells) that are highly tumorigenic and display stem cell-associated properties such as self-renewal and chemoresistance. In contrast, a substantial fraction of HGSC cells is non-tumorigenic. The role of these non-cancer-propagating cells (non-CPCs) and their relationship to CPCs remain poorly understood. Here, we demonstrate that neoplastic cells expressing the intermediate filament protein keratin 5 (KRT5) represent bona fide CPCs. KRT5
Indexed as
cancer cell nichecancer heterogeneitychemoresistanceovarian carcinoma
Identifiers
PMID41659439
PMCPMC12873940
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390